Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
NCT07606105Phase 1Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- May 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Peak Plasma Concentration of total iron in serum, Area under the plasma concentration versus time curve of total iron in serum and 2 more. Started May 2026; status: recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT07606105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606105.